Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E19.59 EPS (ttm)5.71 Insider Own0.02% Shs Outstand2.72B Perf Week-2.71%
Market Cap304.18B Forward P/E15.71 EPS next Y7.12 Insider Trans-8.10% Shs Float2.71B Perf Month-3.08%
Income15.94B PEG3.00 EPS next Q1.56 Inst Own67.00% Short Float0.75% Perf Quarter-0.80%
Sales71.60B P/S4.25 EPS this Y-3.90% Inst Trans-0.06% Short Ratio2.90 Perf Half Y-9.29%
Book/sh26.64 P/B4.20 EPS next Y6.02% ROA11.60% Target Price125.05 Perf Year19.21%
Cash/sh14.86 P/C7.52 EPS next 5Y6.53% ROE22.10% 52W Range93.40 - 124.38 Perf YTD-2.99%
Dividend3.20 P/FCF58.79 EPS past 5Y2.80% ROI14.70% 52W High-10.14% Beta0.75
Dividend %2.86% Quick Ratio2.40 Sales past 5Y2.60% Gross Margin69.60% 52W Low19.66% ATR1.24
Employees127100 Current Ratio2.70 Sales Q/Q4.20% Oper. Margin26.00% RSI (14)30.13 Volatility1.02% 0.99%
OptionableYes Debt/Eq0.37 EPS Q/Q28.20% Profit Margin22.30% Rel Volume1.78 Prev Close113.91
ShortableYes LT Debt/Eq0.32 EarningsJan 24 BMO Payout53.40% Avg Volume7.00M Price111.76
Recom2.50 SMA20-3.07% SMA50-2.62% SMA200-3.48% Volume12,431,240 Change-1.89%
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jan-24-17 05:32PM  Drugmakers Plan Huge Deals in 2017 -- and Banks Will Collect Big Fees
05:02PM  [$$] J&J Stock Undervalued Despite Cautious Forecast at Barrons.com
04:58PM  Johnson & Johnson CEO Talks Trump, Taxes and M&A After Mixed Earnings
04:36PM  J&J HCV Dips To 'Virtually Zero,' Mirroring Gilead; 2017 Views Lag
04:20PM  S&P 500, Nasdaq set records as tech, banks lead
04:10PM  Nasdaq Moves to Fresh All-Time High; Alibaba Posts Blowout Earnings
04:10PM  J&J exploring 'strategic options' for diabetes divisions including one in West Chester at bizjournals.com
03:41PM  Gilead Sciences Stock: What Could Go Wrong? at Motley Fool
03:08PM  Nasdaq approaches new high as stocks gain in afternoon trade
03:08PM  The Grand Divorce
02:28PM  How Will Johnson & Johnson Fare Under President Trump? at Motley Fool
01:37PM  J&J Falls as 4Q Revenue Misses Expectations
01:26PM  J&Js Forecast Disappoints as Actelion Talks Continue
01:26PM  J&Js Forecast Disappoints as Actelion Talks Continue at Bloomberg
01:24PM  [$$] Bad Sign for Pharma in Blockbuster Category's Struggles at The Wall Street Journal
01:12PM  ETFs Today: Homebuilders, MLPs & More Rise On Earnings, Trump at Barrons.com
12:56PM  Johnson & Johnson tumbles into pricing debate after lackluster fourth-quarter drug sales at MarketWatch
12:31PM  Johnson & Johnson CFO Caruso: 'Pleased With the Results'
12:22PM  Johnson & Johnson Opens 2017 on a Cautious Note at Motley Fool
12:17PM  [$$] J&J disappoints on 2017 forecasts due to strong dollar at Financial Times
12:09PM  Johnson & Johnson plans more price transparency; eyes U.S. tax, healthcare changes Reuters
12:07PM  Johnson & Johnson cautious in outlook, shops diabetes care
11:59AM  Johnson & Johnson: Tepid, Cautious, Weak and Other Words You Don't Want to Hear After an Earnings Report at Barrons.com
11:36AM  [$$] Johnson & Johnson Posts Rise in Revenue and Profit, Issues Cautious Forecast at The Wall Street Journal
10:52AM  J&J CFO Cites Currency Factor in Outlook Shortfall
10:52AM  J&J CFO Cites Currency Factor in Outlook Shortfall at Bloomberg
10:52AM  3 ETFs to Buy If You're Impressed With Johnson & Johnson's Fourth Quarter
10:43AM  Hate Risk? You'll Love These 3 Stocks Poised to Keep Outperforming the Market at Motley Fool
10:38AM  How Bristol-Myers Squibbs Oncology Drug Performed in 4Q16
10:32AM  [video]Johnson & Johnson Now Gets a Worrying 45% of Sales From This One Business
10:25AM  Q4 Earnings Roundup: JNJ, VZ, MMM, DD, Etc.
09:54AM  J&J Guides Lower for 2017 Despite Fourth-Quarter Beat at TheStreet
09:41AM  Yahoo jumps on beat, Alibaba revenue soars, Apple gets downgraded
09:30AM  The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies
09:04AM  Morning Movers: Lockheed Martin Tumbles, Johnson & Johnson Slips, AK Steel Soars at Barrons.com
08:50AM  US STOCKS-Wall St set to open flat as earnings season gathers pace
08:35AM  Johnson & Johnson Revenues, 2017 Outlook Weigh on Shares
08:16AM  J&J (JNJ) Beats on Q4 Earnings, Sales Miss; Stock Down
08:15AM  Early movers: DD, VZ, TRV, JNJ, BABA, DHI, MMM & more at CNBC
08:12AM  JOHNSON & JOHNSON Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
08:10AM  US futures mixed as Wall Street focuses on earnings deluge at CNBC
07:38AM  Bristol-Myers Squibbs 4Q16 Estimates: Expect Growth!
07:36AM  What Do Analysts Recommend for Johnson & Johnson?
07:27AM  US STOCKS-Futures flat as earnings season gathers pace
07:07AM  Q4 2016 Johnson & Johnson Earnings Release - Before Market Open
06:59AM  Johnson & Johnson's stock drops after earnings beat but sales missed at MarketWatch
06:50AM  JNJ CFO: Excited to work with Trump adminstration
06:40AM  Johnson & Johnson Reports 2016 Fourth-Quarter Results: PR Newswire
06:23AM  5 Things You Must Know Before the Market Opens Tuesday
05:35AM  Three things to watch beyond Johnson & Johnson's numbers
02:02AM  European Stocks Called Higher amid Dollar Decline, Corporate Earnings Slate
Jan-23-17 09:06PM  The Latest: Trump repeats unproven claim of illegal votes
06:59PM  Will Trump Prove The Trade Critics Wrong? at Forbes
05:23PM  'Unsettled' What you need to know in markets on Tuesday
05:23PM  The Best Earnings Charts on the Street
05:01PM  The Numbers Don't Lie: What Not to Miss in J&J's Earnings
05:01PM  The Numbers Don't Lie: What Not to Miss in J&J's Earnings at Bloomberg
04:29PM  Dow Stocks to Watch for Earnings on Nov 24: DD, JNJ, TRV, VZ
04:28PM  What's Ahead for Healthcare in 2017? at Motley Fool
04:06PM  J&J Snack Foods tops Street 1Q forecasts
12:00PM  Earnings: Last Call for Yahoo? Johnson & Johnson, Alibaba Also Release This Week
11:16AM  CEO's discussed tax, regulations and trade with Trump -Liveris Reuters
11:02AM  What to expect from Johnson & Johnson earnings at MarketWatch
11:01AM  Can Q4 Earnings Revitalize Healthcare ETFs?
10:45AM  Johnson & Johnson to Participate in the Leerink Partners 6th Annual Global Healthcare Conference PR Newswire
10:36AM  Whats New with Johnson & Johnson?
10:15AM  J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio
09:33AM  Trump to company executives: We think we can cut regulations by 75 pct Reuters
09:06AM  Will Johnson & Johnsons Profitability Improve in 4Q16?
08:31AM  10 Questions That Need to Be Asked Ahead of Johnson & Johnson's Q4 Report at Motley Fool
08:30AM  The ECHELON FLEX GST System Will Now Feature A 45mm Endocutter With Exclusive Gripping Surface Technology Reloads PR Newswire
08:06AM  Early movers: HAL, QCOM, MRK, BX, JNJ, TMUS, UAL & more at CNBC
07:38AM  Analysts Expect Negative Growth for Novartis in 4Q16
06:19AM  Actelion Shares Top Swiss Market Despite Opsumit Drug Test Disappointment
05:35AM  Johnson & Johnson Earnings Out Tuesday, What to Expect? at Investopedia
03:53AM  Actelion drug fails trial, denting revenue potential
Jan-22-17 03:24PM  Better Buy: GlaxoSmithKline PLC vs. Johnson & Johnson at Motley Fool
10:35AM  What to Expect From the Dow Stocks Reporting This Week
Jan-21-17 02:02PM  5 Drugs That Are Way Cheaper in Canada at Motley Fool
08:35AM  Earnings Preview: What To Expect From Johnson & Johnson On Tuesday at Forbes
Jan-20-17 08:45PM  Can Johnson & Johnson Sustain Its Growth in 2017? at Motley Fool
12:08PM  Top 10 Multinational Corporations in the US at Insider Monkey
10:36AM  What Does Johnson & Johnson Predict for Its Medical Devices Segment?
10:27AM  Best Dividend Stocks for 2017 at Motley Fool
10:27AM  Johnson & Johnson : JNJ-US: Dividend Analysis : November 22nd, 2016 (record date) : By the numbers : January 20, 2017
09:24AM  [$$] US stocks outlook: cloudy with meatloaves at Financial Times
09:07AM  How Did JNJs Pharmaceuticals Segment Perform in 4Q16?
08:39AM  Johnson & Johnson's Ethicon Endo-Surgery to acquire medical device maker Megadyne Medical Products at MarketWatch
08:30AM  Ethicon Announces Acquisition of Megadyne Medical Products, Inc. PR Newswire
08:02AM  Are You Undervaluing These 3 Biopharmas' Pipelines? at Motley Fool
07:38AM  Why Johnson & Johnsons 4Q16 Revenues Could Grow
02:00AM  Sanofi's M&A misses frustrate some investors in drugmaker Reuters
Jan-19-17 10:48PM  The Latest: Karen Pence hopes to keep advocating art therapy
04:41PM  Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst
04:39PM  What to Expect from Johnson & Johnsons 4Q16 Earnings
04:01PM  Low-Yield Dividend Stocks Belong in Your Portfolio
01:27PM  The Best Dividend Stocks for Long-Term Investors at Motley Fool
01:06PM  Merck, Biogen, Lilly Top 2016 Drug Approvals Despite FDA Slump
11:11AM  A Green Light on Bayer
09:12AM  How Johnson & Johnson Beat Every Other Big Pharma Stock in 2016 at Motley Fool
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM
JOHNSON & JOHNSON10% OwnerAug 16Buy12.00583,3336,999,9962,449,183Aug 18 05:11 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Option Exercise65.6241,1462,700,001157,819Jul 28 04:34 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Sale125.0141,1465,143,810116,673Jul 28 04:34 PM
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM
Kapusta Ronald AController, CAOJul 21Option Exercise58.332,935171,19928,660Jul 25 03:18 PM
Kapusta Ronald AController, CAOJun 07Option Exercise58.333,000174,99028,725Jun 09 04:11 PM
Pruden Gary JExec VP, WW Chair, Med DevicesJun 07Sale116.039,7351,129,55243,630Jun 09 04:12 PM
Kapusta Ronald AController, CAOJun 07Sale115.793,000347,38125,725Jun 09 04:11 PM
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM
Caruso Dominic JVP, Finance; CFOFeb 08Option Exercise0.0029,0050125,466Feb 10 06:02 PM
Gorsky AlexChairman, CEOFeb 08Option Exercise0.0067,9330197,441Feb 10 06:02 PM
PETERSON SANDRA EGroup Worldwide ChairmanFeb 08Option Exercise0.007,633037,943Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 08Option Exercise0.0018,777056,512Feb 10 06:03 PM
Ullmann Michael HVP, General CounselFeb 08Option Exercise0.0016,697098,071Feb 10 06:03 PM
Stoffels PaulusChief Scientific OfficerFeb 08Option Exercise0.0028,2420131,104Feb 10 06:03 PM
Kapusta Ronald AController, CAOFeb 08Option Exercise0.002,598026,023Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Option Exercise72.54144,56810,486,963182,303Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Sale104.12144,56815,052,42037,735Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Option Exercise72.546,817494,50544,552Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Sale104.096,817709,58837,735Feb 04 06:04 PM